Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shoreline Biosciences, Inc.

https://shorelinebio.com/

Latest From Shoreline Biosciences, Inc.

Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets

Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.

Scrip Asks Deals

Chinese Firms At JPM Not About China, It’s Time To Go Global

From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.

China Companies

IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted

Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active. 

Financing Scrip Perspectives

Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines

Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register